Tesamorelinis where the GH secretagogue class gets a footnote that no other member can claim: it carries a genuine FDA approval. Marketed as Egrifta by Theratechnologies, it is approved for reducing excess visceral fat in HIV-positive patients on antiretroviral therapy — making it the only injectable GHRH-receptor agonist with a human RCT trail behind a body-composition endpoint. If your goal is visceral fat reduction and you want the compound with the most clinical backing in this class, Tesamorelin is the answer.
What it is
Tesamorelin is a synthetic analog of full-length GHRH (44 amino acids). The key modification is a trans-3-hexenoic acid group attached at the N-terminus, which increases stability and extends the active half-life compared to native GHRH. It binds pituitary GHRH receptors and triggers a GH pulse in the same way as CJC-1295 and Sermorelin— but with higher potency than Sermorelin and a slightly different pharmacokinetic profile than CJC-1295.
An important mechanistic note: Tesamorelin has no direct lipolytic activity. The visceral fat reduction comes entirely from the GH it causes the pituitary to release. Tesamorelin is the stimulus; GH does the actual work. This matters for understanding why “combining Tesamorelin with exogenous HGH is additive” — you’re not doubling the same mechanism, you’re hitting the axis from two different angles.
What the research actually shows
Tesamorelin is the only GH secretagogue formally studied for visceral fat reduction. The pivotal trials enrolled HIV patients on antiretroviral therapy — a population that develops pronounced visceral adiposity as a treatment side effect. Tesamorelin produced statistically significant reductions in visceral adipose tissue measured by CT over 26 weeks, a result robust enough to earn the Egrifta FDA approval.
The other GH secretagogues (CJC-1295, Ipamorelin, Sermorelin) have not been studied in this context. That doesn’t mean they don’t reduce visceral fat — GH itself does, so any compound that raises GH should move the needle. But the evidence gap between “mechanistically plausible” and “RCT-proven” is real, and Tesamorelin is the only one that has crossed it.
Context matters: the trial populations were meaningfully overweight with antiretroviral-induced fat redistribution. Lean users with already-low body fat should expect a smaller absolute reduction. And for users over 35–40, where pituitary output capacity is declining, the cost-benefit analysis starts to favor exogenous HGH over secretagogue optimization.
How people dose it
Standard reconstitution: 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL. Injection is subcutaneous, fasted.
- Low: 1 mg per injection (20 units on a U-100 syringe), once daily
- Medium: 1–2 mg per injection (20–40 units), once or twice daily
- High: 2 mg per injection (40 units), up to three times daily
Pre-bed and pre-workout are both valid windows. Nocturnal dosing aligns the compound with the largest natural GH pulse; pre-workout takes advantage of exercise-induced GH release. Fasted injection is non-negotiable — food raises insulin, insulin raises somatostatin, somatostatin blocks the signal. Inject at least 2–3 hours after your last meal. Monitor fasted blood glucose weekly; Berberine (500–2,000 mg/day) handles glucose elevation without suppressing IGF-1 the way Metformin does. Typical cycle: 12–16 weeks, then 4 weeks off, then reassess via DEXA or waist circumference.
What it stacks well with
The canonical pairing is Ipamorelin. Tesamorelin covers the GHRH receptor; Ipamorelin covers the ghrelin receptor (GHS-R1a). Dual-receptor stimulation produces a substantially larger GH pulse than either alone — the same logic behind the CJC-1295 + Ipamorelin protocol, but with Tesamorelin as the more potent GHRH arm. The transcript description is direct: “the masculine men amongst us prefer a combination of Tesamorelin and Ipamorelin, maybe injected once, twice, or even three times per day.” If you want maximum injectable secretagogue output, this is the top of the class.
Stacking with exogenous HGH is also supported. Tesamorelin’s visceral fat effect runs through endogenous GH — combining it with exogenous HGH is additive, not redundant. Users already running HGH for muscle or recovery can layer in Tesamorelin for visceral fat without one canceling the other.
The honest caveats
- Cost.Tesamorelin is the most expensive option in the GHRH agonist class. The Tesamorelin + Ipamorelin stack runs roughly $10–36 per day depending on dosage and source — significantly more than comparable HGH. That cost is justified when the specific visceral fat reduction goal or the legal prescription angle is the priority; otherwise, CJC-1295 + Ipamorelin delivers a strong GH pulse at a fraction of the price.
- Pharmacy and compounding status. Unlike CJC-1295, GHRP-2, GHRP-6, MK-677, and Ipamorelin, Tesamorelin is not on the FDA Section 503a restricted list, which means it can still be obtained via US compounding pharmacies by prescription. This prescription pathway is a meaningful distinction for users who want a legal domestic supply.
- Diet discipline is non-negotiable.Tesamorelin amplifies visceral fat loss driven by GH — it does not override a poor diet. The clinical evidence comes from populations where dietary context mattered. Without caloric discipline, the fat-loss signal is blunted.
- Shared GH-class side effects. Water retention, joint stiffness, elevated fasting glucose, and potential carpal tunnel at higher doses apply here as they do across the GH secretagogue class. Dose-dependent and manageable with weekly glucose monitoring and Berberine if needed.
- Drug-screen status.Tesamorelin raises GH and IGF-1. Standard sports drug tests do not screen for secretagogues directly, but elevated GH/IGF-1 ratios may flag depending on the testing protocol. Competitive athletes should verify their specific sport’s testing criteria.
The bottom line
Tesamorelin is the strongest GH secretagogue in this class for visceral fat reduction, and the only one backed by human RCT data on that endpoint. The FDA approval for HIV-associated visceral lipodystrophy is a real clinical anchor, not marketing copy. The mechanism is straightforward: it drives a GH pulse, GH does the lipolytic work, and visceral fat responds.
The cost is the main limiting factor. Stack it with Ipamorelin for the maximum injectable secretagogue protocol; use the Tesamorelin calculator for the reconstitution math. For how Tesamorelin fits in the broader GH secretagogue landscape, read the GH secretagogues post. For full protocol context, the free Peptide Guide covers all the timing and stacking frameworks.